Clinical Trials in Korea Why Korea

Clinical Trials in Korea Why Korea

ID:40056972

大小:1.24 MB

页数:9页

时间:2019-07-18

Clinical Trials in Korea Why Korea_第1页
Clinical Trials in Korea Why Korea_第2页
Clinical Trials in Korea Why Korea_第3页
Clinical Trials in Korea Why Korea_第4页
Clinical Trials in Korea Why Korea_第5页
资源描述:

《Clinical Trials in Korea Why Korea》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库

1、ClinicalTrialsinKorea:WhyKorea?YoungJackLee,Ph.D.PresidentLSKGlobalPharmaServicesSeoul,Koreajacklee@lskglobal.comKoreaisnewtomoderndayclinicaltrials.BeforetheIND(InvestigationalNewDrug)systemwasintroducedin2002,theKoreaFoodandDrugAdministration(KFDA)requiredsafetya

2、ndefficacydataoftheinvestigationalproductforapprovingtheclinicaltrialapplication.Thisrequirementeffectivelyshutdowntrialsofinvestigationalnewproductsbefore2002.Drugtrialsthenweregenerallysmallwith30-90patients.MultinationalsponsorshadnoINDapprovalsbetween1993and200

3、0(seeFigure1).(AnINDtrialbefore2002inKoreaisamisnomer.Itwasasortofbridgingtrial,notanINDtrial.Butforconvenience,Iwillkeepabusingtheterm,IND.)KFDA,whichwasestablishedin1998,approvedfiveINDsformultinationalsponsorsin2000.Thenumberjumpedto17in2002.KFDAapproved148INDsf

4、ormultinationalsponsorsin2007.Thenumberwillbecloseto250thisyear,afiftyfoldincreasefromyear2000(seeFigure2).ThenumberofINDtrialsinKoreaisnowlargerthaninJapan.In1993,therewere160INDapprovalsinJapanand18inKorea.Sincethenthenumberofclinicaltrialshasbeensteadilyincreasi

5、nginKorea,whiledecreasinginJapan.In2002,therewere55INDapprovalsinKoreaand60inJapan.In2005,therewere185INDapprovalsinKoreawhile96inJapan(seeFigure1.),acompletereversalinashortperiod.Chinaisimportantforglobaldrugdevelopment.AccordingtothestatisticspresentedinApril200

6、8attheEastAsianPharmaceuticalRegulatorySymposium2008inTokyo,Japan,however,thenumberofINDapprovalsformultinationalsponsorsinKoreaislargerthaninChina:95in2005,108in2006,and148in2007inKoreawhile31in2005,61in2006,and53in2007inChina(seeFigure2and3).AlthoughChinaisexpect

7、edtocatch-up,atleastfornowKoreaismoreactiveinmultinationaltrialsthanChina.MultinationalsponsorsholdmoreKoreanINDsthandomesticsponsorssince2005.Thistrendwillcontinueandthegapwillgrowevenfurther.FortheJapanesedrugindustrywillincreaseclinicaltrialsinKoreaastheJapanese

8、authorityhasstartedacceptingKoreanclinicaltrialdataforJapaneseregistration.FurthermoretheJapanesegovernmentiscommittedtoregionalclinicaltrialsinv

当前文档最多预览五页,下载文档查看全文

此文档下载收益归作者所有

当前文档最多预览五页,下载文档查看全文
温馨提示:
1. 部分包含数学公式或PPT动画的文件,查看预览时可能会显示错乱或异常,文件下载后无此问题,请放心下载。
2. 本文档由用户上传,版权归属用户,天天文库负责整理代发布。如果您对本文档版权有争议请及时联系客服。
3. 下载前请仔细阅读文档内容,确认文档内容符合您的需求后进行下载,若出现内容与标题不符可向本站投诉处理。
4. 下载文档时可能由于网络波动等原因无法下载或下载错误,付费完成后未能成功下载的用户请联系客服处理。